Section Two: How are we delivering on our strategy?
BUsiness And finAnCiAL review PrinCiPAL risKs And UnCertAinties tHe seCtion BeLow inCLUdes tHe PrinCiPAL risKs And UnCertAinties tHAt tHe GroUP Considers CoULd HAve A siGnifiCAnt effeCt on its finAnCiAL Condition, resULts of oPerAtions or fUtUre PerformAnCe.
tHe List is not set oUt in order of Priority And otHer risKs, CUrrentLy UnKnown or not Considered mAteriAL, CoULd HAve A simiLAr effeCt oPerAtionAL risKs risK PotentiAL imPACt mitiGAtion Compliance with cGMP delays in supply or an Commitment to maintain the inability tomarket or develop highest levels of quality across non-compliance with manufacturing the Groups products allmanufacturing facilities standards often referred to as Current Good manufacturing delayed or denied approvals for the strong global compliance function Practices or cGmP introduction of new products that oversees across theGroup Product complaints or recalls remuneration and reward structurethat helps retain experienced personnel Bans on product sales or importation Continuous staff training disruptions to operations Litigation Regulation restrictions on the sale of one ormore Local operations in most of our of our products key markets Unanticipated legislative and other regulatory actions and developments restrictions on our ability to sell strong oversight of local regulatory concerning various aspects of the ourproducts at a profit requirements to help anticipate potential Groups operations and products changes to the regulatory environments Unexpected additional costs required to in which we operate produce, market orsellour products representation and or affiliation with increased compliance costs local industry bodies Commercialisation of new products slowdown in revenue growth experienced regulatory teams able to from new products accelerate submission processes across delays in the receipt of marketing all of our markets approvals, the authorisation of price and inability to deliver a positive reimbursement returnon investments in r&d, Highly qualified sales and marketing manufacturing and sales teams across all markets Lack of approval and acceptance of new and marketing products by physicians, patients and A diversified product pipeline with63 new other key decision-makers compounds pending approval, covering a broad range oftherapeutic areas inability to confirm safety, efficacy, convenience and or costA systematic commitment to quality effectiveness of our products as that helps to secure approval and compared tocompetitive products acceptance of newproducts and mitigate potential safety issues inability to participate in tendersales 29
